|
DIRC2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.49860000034863E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.44870000000375E-05 |
| Normal-vs-Stage2 |
2.482200E-02 |
| Normal-vs-Stage3 |
5.34339994473498E-09 |
| Normal-vs-Stage4 |
3.01869999996818E-07 |
| Stage1-vs-Stage2 |
2.967000E-01 |
| Stage1-vs-Stage3 |
1.259550E-02 |
| Stage1-vs-Stage4 |
2.976200E-02 |
| Stage2-vs-Stage3 |
6.080800E-03 |
| Stage2-vs-Stage4 |
1.233670E-02 |
| Stage3-vs-Stage4 |
7.404200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.45860000136489E-08 |
| Normal-vs-AfricanAmerican |
5.763800E-03 |
| Normal-vs-Asian |
2.33819999999607E-05 |
| Caucasian-vs-AfricanAmerican |
4.467600E-01 |
| Caucasian-vs-Asian |
8.814200E-01 |
| AfricanAmerican-vs-Asian |
5.186200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.420950E-04 |
| Normal-vs-Female |
3.31770000028264E-07 |
| Male-vs-Female |
5.592800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.5732000000066E-05 |
| Normal-vs-Age(41-60Yrs) |
1.37560000001979E-06 |
| Normal-vs-Age(61-80Yrs) |
2.36189999999192E-05 |
| Normal-vs-Age(81-100Yrs) |
6.803600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.909400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.564400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.133800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.792800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.475600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.712000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.455530E-03 |
| Classical-VS-Follicular |
1.039940E-02 |
| Classical-VS-Other |
4.248000E-01 |
| Classical-VS-Normal |
1.31399999991899E-07 |
| Tall-VS-Follicular |
1.75619999999155E-05 |
| Tall-VS-Other |
6.724200E-01 |
| Tall-VS-Normal |
8.12189981935774E-10 |
| Follicular-VS-Other |
1.643450E-01 |
| Follicular-VS-Normal |
5.664500E-02 |
| Other-VS-Normal |
6.644500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.46619999999931E-05 |
| Normal-vs-N1 |
5.00090000521425E-08 |
| N0-vs-N1 |
2.086300E-02 |
|
|
